{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:46Z","timestamp":1777934566165,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>For young adult patients with acute leukemia, both the efficacy and cardiotoxicity of anthracycline-based regimens have been documented. We report the case of a patient with severe cardiomyopathy, mechanically supported by a left ventricular assist device (LVAD), who subsequently developed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). To our knowledge, this is the first report of anthracycline administration in a patient with heart failure requiring mechanical support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>Our 27-year-old female patient was diagnosed with Ph\u2009+\u2009B-ALL as part of workup for leukocytosis. Past medical history included non-ischemic cardiomyopathy with a left ventricular ejection fraction of 30\u201335% and moderate-severe right ventricular dysfunction, for which LVAD had been placed 4 years previously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; outcome<\/jats:title>\n                    <jats:p>After shared decision-making and multidisciplinary discussions, we felt that hyperfractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone alternating with cytarabine and high-dose methotrexate in addition to ponatinib (HyperCVAD-ponatinib) best balanced the patient's goals for aggressive treatment with the potential for rapid and durable remissions. The patient received a single reduced dose of doxorubicin alongside dexrazoxane with her first cycle of HyperCVAD-ponatinib. She attained a complete molecular response 22 days later and remains in remission (with stable cardiac function) 30 months later on maintenance therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In conclusion, LVAD placement is not an absolute contra-indication to anthracyclines if such therapies offer the best opportunity for a durable response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211062148","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T14:28:23Z","timestamp":1638282503000},"page":"729-732","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pharmacy, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liviu","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandar","family":"Aras","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"bibr1-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746"},{"key":"bibr2-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627935"},{"key":"bibr3-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.7228"},{"key":"bibr4-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"bibr5-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.116"},{"key":"bibr6-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30176-5"},{"key":"bibr7-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30231"},{"key":"bibr8-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.07.007"},{"key":"bibr9-10781552211062148","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1036259"},{"key":"bibr10-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219877931"},{"key":"bibr11-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-019-0036-7"},{"key":"bibr12-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000000116"},{"key":"bibr13-10781552211062148","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezv203"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211062148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211062148","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211062148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:47Z","timestamp":1777688747000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211062148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/10781552211062148"],"URL":"https:\/\/doi.org\/10.1177\/10781552211062148","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}